[Abstract Only] Randomized Trial: Different Doses of Adjuvant Ipilimumab vs. High-Dose Interferon Alfa-2b in Patients with Resected High-Risk Melanoma

Different Doses of Adjuvant Ipilimumab vs High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma – The ASCO Post (free)

Original Study: Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609 – Journal of Clinical Oncology (link to abstract – $ for full-text)